Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ALNY Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy.
Vutrisiran Met All 18-Month Secondary Endpoints
$OCUL ™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis Ocular Therapeutix, Inc.
$SUPN to acquire $ADMS for $8.10/ share in cash
PCRX to acquire $FLXN for $8.50/share in cash
$CCXI Announces FDA Approval of TAVNEOS (avacopan) in ANCA-Associated Vasculitis
MERCK SAID TO AGREE TO $180-PER-SHARE CASH DEAL FOR ACCELERON
Merck Nears Deal to Acquire $XLRN
$XLRN Deal Could Be Completed as Soon as This Week, Sources Say
Drugmaker $XLRN Acceleron Pharma Inc. is in advanced discussions to be acquired by a large pharmaceutical company for about $180 a share in cash, according to people familiar with the matter.
Any thoughts on the LPTX data the other day?
ZOLL Medical to acquire $ITMR for $31/ADS
FBRX Phase 2 Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
Great stock. Fantastic financials released today
CARA gets fda approval. https://finance.yahoo.com/news/cara-therapeutics-vifor-pharma-announce-194100559.html
Isn’t their drug really just like cough syrup?
Data doesn’t look good. Did trials really fail?
The stock has been tumbling for a while now. I am guessing wind of this termination made the rounds before it went public today
DRNA announces positive data https://finance.yahoo.com/news/dicerna-reports-positive-top-line-200100927.html
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
https://www.businesswire.com/news/home/20210729006225/en/BeiGene-Announces-Positive-Topline-Results-from-Phase-3-SEQUOIA-Trial-Comparing-BRUKINSA%C2%AE-Zanubrutinib-to-Bendamustine-Plus-Rituximab-in-Patients-with-Treatment-Na%C3%AFve-Chronic-Lymphocytic-Leukemia
Clinical hold for MGTA
The FDA is requiring that Magenta develop an additional bioassay to be used in conjunction with the PK/PD model to inform dose escalation decisions in addition to safety monitoring
ALEC/GSK announce partnership https://finance.yahoo.com/news/alector-gsk-announce-global-collaboration-113800677.html